Letizia Canu, MD, PhD 

Nata a Prato, 8 Febbraio 1982

Nazionalità: Italiana

Indirizzo: Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università degli Studi di Firenze, Viale Pieraccini 6, 50139 Firenze – Italia

FORMAZIONE

2009     Laurea in Medicina e Chirurgia presso Università degli Studi di Firenze 108/110 con tesi dal titolo “Gli effetti anti proliferativi del Rosiglitazone nel carcinoma corticosurrenalico: risultati in vitro ed in vivo”

2016     Specializzazione in Endocrinologia presso Università degli Studi di Firenze: 70/70 cum laude con tesi dal titolo “La terapia del feocromocitoma/paraganglioma metastatico: un problema irrisolto”. 

2019     Dottorato di Ricerca in Scienze Biomediche con tesi dal titolo “Feocromocitoma/paraganglioma: aspetti radiologici ed associazione con secondi tumori". 

POSIZIONE ATTUALE, CARRIERA ACCADEMICA

2016-2021 Assegno di Ricerca assistenziale presso la SOD di Endocrinologia dell’Azienda Opsedaliero Universitaria di Careggi

2016-2019 Dottorato di Ricerca con attività assistenziale in Biotecnologie Endocrinologiche, molecolari e rigenerative presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche dell’Università degli Studi di Firenze

Da Settembre 2021 RTDA con assistenza presso la SOD di Endocrinologia dell’Azienda Opsedaliero Universitaria di Careggi

METRICHE

N=70 articoli pubblicati su riviste Internazionali (IF: 347.684; mean IF: 5.893)

N=9 pubblicati in riviste Italiane, n=4 capitoli di un libro

N>100 abstracts a Congressi Nazionali ed Internazionali

Scopus: H-index = 24; Citazioni = 1714

PARTECIPAZIONE A SOCIETÀ SCIENTIFICHE

Membro di European network for the study of Adrenal Tumor (ENS@T); Membro della Società Italiana di Endocrinologia (SIE); Membro di European Society of Endocrinology (ESE); Membro della Associazione Medici Endocrinologi (AME); Membro della commissione scientifica del Club Endocrinologia Giovane in Italia (EnGioI) dal 26/09/2015 al 31/05/2019; Referente per il centro Italia del gruppo giovani di AME dal 15/02/2021 ad oggi; Membro del comitato editorale dell’Endocrinologo dal 05/10/2023; Segretario del Club Surrene della SIE dal 25/10/2023

ATTIVITÀ EDITORIALE

2018 - 2022      Membro dell’Editorial Board del Journal of Endocrinological Investigation (JEI)

2021 -2022       Review Editor della rivista Frontiers in Endocrinology

Reviewer per molte riviste scientifiche (Cancers, Current Trends in Internal Medicine, Endocrine, Endocrine Connection, European Journal of Endocrinology, Frontiers in Endocrinology, Genetics in Medicine, Journal of Current Trends in Internal Medicine, Journal of Clinical Endocrinology & Metabolism, Journal of Endocrinological Investigation, Journal of Medical Genetics, Journal of Surgical, Endocrinology, OncoTargets and Therapy)

INSEGNAMENTO (dal 2016 ad oggi)

Correlatore tesi in Medicina e Chirurgia (n14)

Attività di insegnamento Scuola di specializzazione in Endocrinolgia

Attività di tutoraggio Corso di Laurea in Medicina e Chirurgia

PUBBLICAZIONI SELEZIONATE (2010-2023)

1. Canu L, …, Mannelli M. Pitfalls in Genetic Analysis of Pheochromocytomas/Paragangliomas: Case Report. J Clin Endocrinol Metab.  2014;99(7):2321-6. doi: 10.1210/jc.2013-4453. IF=5.399
2. Papathomas TG, …, Canu L, …, de Krijger RR. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol. 2015;28(6):807-21. doi: 10.1038/modpathol.2015.41. IF=5.988
3. Salvianti F*, Canu L*, …, Pinzani P and Luconi M. New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer. Oncotarget. 2017;8(39):65525-65533. doi: 10.18632/oncotarget.19118. IF=5.168. *These authors have equally contributed to the work
4. Canu L, …, Timmers HJLM. CT characteristics of pheochromocytoma - Relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab. 2019;104(2):312-318. doi: 10.1210/jc.2018-01532. IF=5.399
5. Castinetti F, …, Canu L, …, Baudin E. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019;7(3):213-220. doi: 10.1016/S2213-8587(18)30336-X. IF=25.34
6. Hescot S, …, Canu L, …, Baudin E; European Network for the Study of Adrenal Tumors (ENS@T). Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab. 2019;104(6):2367-2374. doi: 10.1210/jc.2018-01968. IF= 5.399
7. Rao D, …, Canu L, …, Timmers HJLM. Impact of 123 I_MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2019;jc.2018-02355. doi: 10.1210/jc.2018-02355. IF= 5.399
8. Calsina B, …, Canu L, …, Robledo M. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics 2019;9(17):4946-4958. doi: 10.7150/thno.35458. IF=8.579
9. Altieri B, …, Canu L, …, Ronchi CL. Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers (Basel). 2020;12(2):359. doi: 10.3390/cancers12020359. IF=6.126
10. Doghman-Bouguerra M, …, Canu L, …, Lalli E. Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. Cancers (Basel). 2020;12(3):689. doi: 10.3390/cancers12030689. IF= 6.126
11. De Filpo G, …, Canu L. Germline Mutation in KIF1Bβ Gene Associated with Loss of Heterozygosity: Usefulness of Next-Generation Sequencing in the Genetic Screening of Patients with Pheochromocytoma. Int J Endocrinol. 2020;3671396. doi: 10.1155/2020/3671396. IF=2.299
12. De Filpo G, …, Canu L. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview. J Endocrinol Invest. 2020. doi: 10.1007/s40618-020-01344-z. IF=3.397
13. Bancos I, …, Canu L, …, Arlt W; ENSAT EURINE-ACT Investigators. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020;8(9):773-781.doi: 10.1016/S2213-8587(20)30218-7.  IF=25.340
14. Cantini G, Canu L, …, Luconi M. Prognostic and monitoring value of circulating tumour cells in adrenocortical carcinoma: a preliminary monocentric study. Cancers 2020, 12(11):E3176. doi: 10.3390/cancers12113176. IF=6.126
15. Crona J,  …, Canu L, …, Beuschlein F. ENSAT Registry-Based Randomized Clinical Trials for Adrenocortical Carcinoma. Eur J Endocrinol. 2020:EJE-20-0800.R1. doi: 10.1530/EJE-20-0800. IF=5.308
16. De Filpo G, …, Canu L. Adrenocortical carcinoma: current treatment options. Curr Opin Oncol. 2021;33(1):16-22. doi: 10.1097/CCO.0000000000000695. IF=3.370
17. Murakami M, …, Canu L, …, Beuschlein F. Mass Spectrometry Imaging Identifies Metabolic Patterns Associated with Malignant Potential in Pheochromocytoma and Paraganglioma. Eur J Endocrinol. 2021:EJE-20-1407.R1. doi: 10.1530/EJE-20-1407.  IF= 5.308
18. Velema MS, Canu L, …, Deinum J; SPARTACUS Investigators. Volumetric evaluation of CT images of adrenal glands in primary aldosteronism. J Endocrinol Invest. 2021. doi: 10.1007/s40618-021-01540-5. IF= 3.397
19. Basile V, …, Canu L, …, Terzolo M. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. J Pers Med. 2021;11(4):269. doi: 10.3390/jpm11040269. IF= 4.433
20. Cantini G, …, Canu L, …, Luconi M. Circulating fascin 1 as a promising prognostic marker in adrenocortical cancer. Front Endocrinol (Lausanne). 2021;12:698862. doi: 10.3389/fendo.2021.698862. IF=5.468
21. De Filpo G, …, Canu L. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience. J Endocrinol Invest. 2021. doi: 10.1007/s40618-021-01629-x. IF=3.16
22. Monteagudo M, …, Canu L, …, Robledo M. Analysis of telomere maintenance related genes reveals nop10 as a new metastatic-risk marker in PPGL. Cancers (Basel). 2021 Sep 23;13(19):4758. doi: 10.3390/cancers13194758. IF= 6.639
23. Cantini G, …, Canu L, …, Maggi M and Luconi M. Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression. J Pers Med. 2021 Oct 27;11(11):1097. doi: 10.3390/jpm11111097.  IF= 4.453
24. Elhassan YS, …, Canu L, …, Ronchi CL. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol. 2021 Nov 30;186(1):25-36. doi: 10.1530/EJE-21-0510. IF=6.341
25. Canu L, …, Reimondo G. A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers (Basel). 2021 Nov 20;13(22):5831. doi: 10.3390/cancers13225831. IF=6.639
26. Prete A, …, Canul L, …, Arlt W; ENSAT EURINE-ACT Investigators*; ENSAT EURINE-ACT Investigators. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors: A Cross-Sectional Multicenter Study. Ann Intern Med 2022;175(3):325-334. doi: 10.7326/M21-1737. IF= 25.391
27. Canu L, …, Peri A. Case Report: Adrenocortical Oncocytoma in a Patient with a Previous Contralateral Adrenalectomy for a Cortisol-Secreting Adenoma.  Front Surg. 2022 19;9:897967. doi: 10.3389/fsurg.2022.897967. IF= 2.568
28. Provenzano A, …, Canu L. Novel Germline PHD2 Variant in a Metastatic Pheochromocytoma and Chronic Myeloid Leukemia, but in the Absence of Polycythemia. Medicina (Kaunas). 202217;58(8):1113. doi: 10.3390/medicina58081113.  IF= 2.985
29. Fei L, … Canu L, … Luconi M. Carbonic anhydrases III and IX are new players in the crosstalk between adrenocortical carcinoma and its altered adipose microenvironment. J Endocrinol Invest. 2023. doi: 10.1007/s40618-023-02008-4. IF= 4.256
30. Mellid S, … Canu L, … Cascón A. Co-occurrence of mutations in NF1 and other susceptibility genes in pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2023;13:1070074. doi: 10.3389/fendo.2022.1070074. IF= 6.055
31. Luconi M, … Canu L, … Nesi G. Prognostic Value of Microscopic Tumor Necrosis in Adrenal Cortical Carcinoma. Endocr Pathol. 2023. doi: 10.1007/s12022-023-09760-6. IF=3.943
32. Puglisi S, … Canu L, … Terzolo M. New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study. J Clin Endocrinol Metab. 2023:dgad199. doi: 10.1210/clinem/dgad199. IF=6.134
33. Martinelli S, … Canu L, … Rapizzi E. Tumour microenvironment in pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2023;14:1137456. doi: 10.3389/fendo.2023.1137456. IF= 6.055
34. De Filpo G, … Canu L.   Hemodynamic parameters in patients undergoing surgery for pheochromocytoma/paraganglioma: a retrospective study. World J Surg Onco. 2023;21(1):192. doi: 10.1186/s12957-023-03072-z. IF= 2.754
35. Amore F, …, Canu L, Rapizzi E. The aggressiveness of SDHB deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide. Endocr Relat Cancer. 2023 Jul 1:ERC-23-0167. doi: 10.1530/ERC-23-0167.  IF= 3.9
36. Amore F, …Canu L, …, Rapizzi E. The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide. Endocr Relat Cancer. 2023;30(10):e230167. doi: 10.1530/ERC-23-0167. IF= 3.9

Letizia Canu, MD, PhD 

Born in Prato (Italy), February 8, 1982

Nationality: Italian

Business address: Dept. Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Pieraccini 6, 50139 Florence – Italy

PROFESSIONAL INFORMATION

Letizia Canu is an MD, Endocrinologist, PhD in Endocrinology & Metabolism. Since 2009, she has been working in the clinical and biology of endocrine tumors, with particular focus on adrenocortical carcinoma and Pheochromocytoma/paraganglioma in collaboration with Prof. M. Mannelli. 

EDUCATION

2009     Degree in Medicine and Surgery at University of Florence: 108/110. Experimental thesis “Rosiglitazone Anti-proliferative effects in adrenocortical carcinoma: in vitro and in vivo results”

2016     Specialization in Endocrinology University of Florence: 70/70 cum laude. Experimental thesis “Therapies in metastatic pheochromocytoma/paraganglioma: an unsolved problem”. 

2019     PhD in Biomedical Sciences. PhD thesis: “Pheochromocytoma/paraganglioma: radiological aspects and association with second malignant tumors ".”.

CURRENT POSITION – ACADEMIC CAREER

2016-2021 Clinical researcher fellow in Endocrinology with medical assistance at Endocrinology Unit, University Hospital of Florence

2016-2019 PhD in Endocrinological, molecular and regenerative biotechnologies at Dept. Clinical Physiopathology, University of Florence. 

From September 2021 Clinical researcher in Endocrinology with medical assistance at Endocrinology Unit, University Hospital of Florence

SCIENTIFIC METRICS

N=70 papers in peer-review International journals (IF: 347.684; mean IF: 5.893)

N=9 paper in national journal, n=4 book chapter

N>100 abstracts at National and International Meetings

Scopus: H-index = 24; Citations = 1714

MEMBERSHIP

European network for the study of Adrenal Tumor (ENS@T); Italian Society of Endocrinology (SIE); European Society of Endocrinology (ESE); Association of Italian Endocrinologist (AME); Member of Scientific Commission of Club Endocrinologia Giovane in Italia (EnGioI) from 26/09/2015 to 31/05/2019; AME GAME referent for the center of Italy from 15/02/2021 at present; Member of the editorial board of journal L’Endocrinologo  from  October 2023; Secretary of the SIE Adrenal Club from October 2023

EDITORIAL ACTIVITY

2018 - 2022      Editorial Board of Journal of Endocrinological Investigation (JEI)

2021 -2022       Review Editor for Frontiers in Endocrinology

Reviewer for the following scientific journals (Cancers, Current Trends in Internal Medicine, Endocrine, Endocrine Connection, European Journal of Endocrinology, Frontiers in Endocrinology, Genetics in Medicine, Journal of Current Trends in Internal Medicine, Journal of Clinical Endocrinology & Metabolism, Journal of Endocrinological Investigation, Journal of Medical Genetics, Journal of Surgical, Endocrinology, OncoTargets and Therapy)

TEACHING ACTIVITY

2016-present    Tutoring activity of n>10 undergraduates in Medicine and Surgery 

Supervisor and mentor of thesis (n13) 

Teaching activity in School in Endocrinology

Tutoring activity in Degree in Medicine and Surgery

            SELECTED PUBLICATIONS (2010-2023)

1. Canu L, …, Mannelli M. Pitfalls in Genetic Analysis of Pheochromocytomas/Paragangliomas: Case Report. J Clin Endocrinol Metab.  2014;99(7):2321-6. doi: 10.1210/jc.2013-4453. IF=5.399
2. Papathomas TG, …, Canu L, …, de Krijger RR. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol. 2015;28(6):807-21. doi: 10.1038/modpathol.2015.41. IF=5.988
3. Salvianti F*, Canu L*, …, Pinzani P and Luconi M. New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer. Oncotarget. 2017;8(39):65525-65533. doi: 10.18632/oncotarget.19118. IF=5.168. *These authors have equally contributed to the work
4. Canu L, …, Timmers HJLM. CT characteristics of pheochromocytoma - Relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab. 2019;104(2):312-318. doi: 10.1210/jc.2018-01532. IF=5.399
5. Castinetti F, …, Canu L, …, Baudin E. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019;7(3):213-220. doi: 10.1016/S2213-8587(18)30336-X. IF=25.34
6. Hescot S, …, Canu L, …, Baudin E; European Network for the Study of Adrenal Tumors (ENS@T). Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab. 2019;104(6):2367-2374. doi: 10.1210/jc.2018-01968. IF= 5.399
7. Rao D, …, Canu L, …, Timmers HJLM. Impact of 123 I_MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2019;jc.2018-02355. doi: 10.1210/jc.2018-02355. IF= 5.399
8. Calsina B, …, Canu L, …, Robledo M. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics 2019;9(17):4946-4958. doi: 10.7150/thno.35458. IF=8.579
9. Altieri B, …, Canu L, …, Ronchi CL. Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers (Basel). 2020;12(2):359. doi: 10.3390/cancers12020359. IF=6.126
10. Doghman-Bouguerra M, …, Canu L, …, Lalli E. Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. Cancers (Basel). 2020;12(3):689. doi: 10.3390/cancers12030689. IF= 6.126
11. De Filpo G, …, Canu L. Germline Mutation in KIF1Bβ Gene Associated with Loss of Heterozygosity: Usefulness of Next-Generation Sequencing in the Genetic Screening of Patients with Pheochromocytoma. Int J Endocrinol. 2020;3671396. doi: 10.1155/2020/3671396. IF=2.299
12. De Filpo G, …, Canu L. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview. J Endocrinol Invest. 2020. doi: 10.1007/s40618-020-01344-z. IF=3.397
13. Bancos I, …, Canu L, …, Arlt W; ENSAT EURINE-ACT Investigators. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020;8(9):773-781.doi: 10.1016/S2213-8587(20)30218-7.  IF=25.340
14. Cantini G, Canu L, …, Luconi M. Prognostic and monitoring value of circulating tumour cells in adrenocortical carcinoma: a preliminary monocentric study. Cancers 2020, 12(11):E3176. doi: 10.3390/cancers12113176. IF=6.126
15. Crona J,  …, Canu L, …, Beuschlein F. ENSAT Registry-Based Randomized Clinical Trials for Adrenocortical Carcinoma. Eur J Endocrinol. 2020:EJE-20-0800.R1. doi: 10.1530/EJE-20-0800. IF=5.308
16. De Filpo G, …, Canu L. Adrenocortical carcinoma: current treatment options. Curr Opin Oncol. 2021;33(1):16-22. doi: 10.1097/CCO.0000000000000695. IF=3.370
17. Murakami M, …, Canu L, …, Beuschlein F. Mass Spectrometry Imaging Identifies Metabolic Patterns Associated with Malignant Potential in Pheochromocytoma and Paraganglioma. Eur J Endocrinol. 2021:EJE-20-1407.R1. doi: 10.1530/EJE-20-1407.  IF= 5.308
18. Velema MS, Canu L, …, Deinum J; SPARTACUS Investigators. Volumetric evaluation of CT images of adrenal glands in primary aldosteronism. J Endocrinol Invest. 2021. doi: 10.1007/s40618-021-01540-5. IF= 3.397
19. Basile V, …, Canu L, …, Terzolo M. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. J Pers Med. 2021;11(4):269. doi: 10.3390/jpm11040269. IF= 4.433
20. Cantini G, …, Canu L, …, Luconi M. Circulating fascin 1 as a promising prognostic marker in adrenocortical cancer. Front Endocrinol (Lausanne). 2021;12:698862. doi: 10.3389/fendo.2021.698862. IF=5.468
21. De Filpo G, …, Canu L. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience. J Endocrinol Invest. 2021. doi: 10.1007/s40618-021-01629-x. IF=3.16
22. Monteagudo M, …, Canu L, …, Robledo M. Analysis of telomere maintenance related genes reveals nop10 as a new metastatic-risk marker in PPGL. Cancers (Basel). 2021 Sep 23;13(19):4758. doi: 10.3390/cancers13194758. IF= 6.639
23. Cantini G, …, Canu L, …, Maggi M and Luconi M. Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression. J Pers Med. 2021 Oct 27;11(11):1097. doi: 10.3390/jpm11111097.  IF= 4.453
24. Elhassan YS, …, Canu L, …, Ronchi CL. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol. 2021 Nov 30;186(1):25-36. doi: 10.1530/EJE-21-0510. IF=6.341
25. Canu L, …, Reimondo G. A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers (Basel). 2021 Nov 20;13(22):5831. doi: 10.3390/cancers13225831. IF=6.639
26. Prete A, …, Canul L, …, Arlt W; ENSAT EURINE-ACT Investigators*; ENSAT EURINE-ACT Investigators. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors: A Cross-Sectional Multicenter Study. Ann Intern Med 2022;175(3):325-334. doi: 10.7326/M21-1737. IF= 25.391
27. Canu L, …, Peri A. Case Report: Adrenocortical Oncocytoma in a Patient with a Previous Contralateral Adrenalectomy for a Cortisol-Secreting Adenoma.  Front Surg. 2022 19;9:897967. doi: 10.3389/fsurg.2022.897967. IF= 2.568
28. Provenzano A, …, Canu L. Novel Germline PHD2 Variant in a Metastatic Pheochromocytoma and Chronic Myeloid Leukemia, but in the Absence of Polycythemia. Medicina (Kaunas). 202217;58(8):1113. doi: 10.3390/medicina58081113.  IF= 2.985
29. Fei L, … Canu L, … Luconi M. Carbonic anhydrases III and IX are new players in the crosstalk between adrenocortical carcinoma and its altered adipose microenvironment. J Endocrinol Invest. 2023. doi: 10.1007/s40618-023-02008-4. IF= 4.256
30. Mellid S, … Canu L, … Cascón A. Co-occurrence of mutations in NF1 and other susceptibility genes in pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2023;13:1070074. doi: 10.3389/fendo.2022.1070074. IF= 6.055
31. Luconi M, … Canu L, … Nesi G. Prognostic Value of Microscopic Tumor Necrosis in Adrenal Cortical Carcinoma. Endocr Pathol. 2023. doi: 10.1007/s12022-023-09760-6. IF=3.943
32. Puglisi S, … Canu L, … Terzolo M. New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study. J Clin Endocrinol Metab. 2023:dgad199. doi: 10.1210/clinem/dgad199. IF=6.134
33. Martinelli S, … Canu L, … Rapizzi E. Tumour microenvironment in pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2023;14:1137456. doi: 10.3389/fendo.2023.1137456. IF= 6.055
34. De Filpo G, … Canu L.   Hemodynamic parameters in patients undergoing surgery for pheochromocytoma/paraganglioma: a retrospective study. World J Surg Onco. 2023;21(1):192. doi: 10.1186/s12957-023-03072-z. IF= 2.754
35. Amore F, …, Canu L, Rapizzi E. The aggressiveness of SDHB deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide. Endocr Relat Cancer. 2023 Jul 1:ERC-23-0167. doi: 10.1530/ERC-23-0167.  IF= 3.9
36. Amore F, …Canu L, …, Rapizzi E. The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide. Endocr Relat Cancer. 2023;30(10):e230167. doi: 10.1530/ERC-23-0167. IF= 3.9